Background: APX001A is an antifungal agent that targets a novel pathway-glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi.
Objectives: To determine the activity of APX001A against the emerging fungal pathogen Candida auris.
Methods: APX001A was tested by broth microdilution against 100 geographically distinct isolates of C. auris.
Results: APX001A showed activity against all isolates, including some that were resistant to one or more antifungals, with MIC50 and MIC90 of 0.002 and 0.008 mg/L, respectively.
Conclusions: These findings suggest that APX001A shows encouraging activity against the emerging fungal pathogen C. auris.